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Abstract In rat brain astroglia-enriched cultures long-term
treatment with interleukin-1L induces NO release and stimula-
tion of soluble guanylyl cyclase. The cGMP formed is recovered
in the extracellular medium but not in the cell monolayer. The
interleukin-1L effect is mediated by type I receptor and
potentiated by interferon-Q. In cells treated with bacterial
endotoxin a larger NO-dependent cGMP accumulation occurs
only intracellularly, however a significant cGMP egression is
observed when cells are co-treated with interleukin-1L. The non-
selective anion transport inhibitors probenecid and verapamil
block cGMP efflux, indicating that interleukin-1L stimulates a
cGMP transporter. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The presence of cyclic nucleotides in extracellular £uids in-
cluding plasma, urine and cerebrospinal £uid has been known
for a long time. cGMP, ¢rst discovered in urine [1], is released
to the extracellular milieu in several tissues including liver [2],
brain [3], pancreas [4], smooth muscle [5], platelets [6] and
erythrocytes [7]. In these later cells an ATP-dependent trans-
porter appears to be involved in cGMP extrusion [7,8]. In
most studies, e¥ux of cGMP was related to the intracellular
concentration of the nucleotide and interpreted as a mecha-
nism that in conjunction with the action of phosphodiester-
ases would return intracellular cGMP to basal levels. How-
ever, recent studies in neural cells suggest that extracellular
cGMP may exert physiological actions by regulating the ac-
tivity of membrane proteins through interaction with extracel-
lular sites. For instance, in cerebellar granule neurons extra-
cellular cGMP has been shown to inhibit cellular responses
mediated by kainate receptors [8] and to protect against glu-
tamate-induced toxicity [9]. In cortical astrocytes, cGMP re-
leased after stimulation of particulate guanylyl cyclase by na-
triuretic peptides inhibits a Na/H exchanger leading to a
decrease in intracellular pH, an e¡ect that could modulate
important astroglial functions such as K conductance or
cell proliferation [10]. In this work, we show for the ¢rst
time that the cGMP formed in rat brain astrocyte cultures
after induction of NO release and stimulation of soluble gua-
nylyl cyclase (sGC) by the pro-in£ammatory cytokine inter-
leukin-1L (IL-1L) accumulates in the extracellular but not in
the intracellular medium. IL-1L also stimulates the release of
cGMP formed after induction of NO synthase (NOS) by the
bacterial endotoxin, lipopolysaccharide (LPS) and the e¡ect
appears to involve stimulation of a transporter.
2. Materials and methods
Dulbecco’s modi¢ed Eagle’s medium (DMEM) was obtained from
Flow Laboratories and fetal calf serum (FCS) from Biological Indus-
tries; [3H]cGMP (34.5 Ci/mmol) was from New England Nuclear; IL-
1L, interferon-Q (INF-Q) and tumor necrosis factor-K (TNF-K) from
PeproTechec; LPS (Salmonella typhimurium), NG-monomethyl-L-
arginine (L-NMMA), 1H-[1,2,4]oxodiazolo-[4,3-a]quinoxalin-1-one
(ODQ), probenecid, verapamil, IL-1 receptor antagonist protein (IL-
1Ra) from Sigma; anti-cGMP antiserum was prepared in our labora-
tory as described by Brooker et al. [11].
Astrocyte-enriched primary cultures were prepared from newborn
(cortex and hippocampus) and 7-day-old (cerebellum) Sprague^Daw-
ley rats as described ([12]). Dissociated cells suspended in DMEM^
10% FCS, were seeded in 35 mm diameter plastic Petri dishes
(1.25U105 cells/cm2). Medium was changed once a week and cells
were used after 14 days in culture. Cells were incubated for the in-
dicated times with IL-1L or other agents in serum-free media. Cell
viability of cytokine-treated astrocytes was determined by measuring
release of lactate dehydrogenase (LDH) to the medium [13].
cGMP levels were measured in cell monolayers and in the incuba-
tion media after the indicated treatments. Media was aspirated and
cell monolayers were washed with HEPES-bu¡ered saline (118 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 10 mM glucose and 20 mM HEPES, pH 7.4) at 37‡C and
extracted with ice-cold ethanol. Media and ethanolic cell extracts were
evaporated and residues dissolved in 5 mM sodium acetate pH 4.8.
cGMP was quanti¢ed by RIA using acetylated [3H]cGMP as de-
scribed [14]. Nitrites accumulated in cell incubation media were de-
termined by the Greiss reaction [15]. Protein concentration was deter-
mined by the method of Lowry et al. using BSA as standard.
Experiments were always performed in triplicates. Results are ex-
pressed as mean þ S.E.M. of the indicated number of experiments
performed in di¡erent culture preparations.
3. Results and discussion
As shown in Fig. 1, treatment of rat cerebellar astrocyte-
enriched cultures with the pro-in£ammatory cytokine IL-1L
induced a time- (Fig. 1A) and concentration-dependent (Fig.
1C) accumulation of cGMP in the extracellular medium but
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not in the cell monolayer. Extracellular cGMP in cells treated
with a maximally e¡ective concentration of IL-1L (10 ng/ml)
was higher than in control cells after 3 h and increased line-
arly for at least 20 h, while intracellular cGMP remained at
control levels. IL-1L also produced an increase in nitrites in
the media with a similar time and concentration dependency
(Fig. 1B,D), suggesting that accumulated cGMP results from
IL-1L induction of NOS and NO stimulation of sGC. In fact,
extracellular cGMP accumulation was totally blocked by the
NOS inhibitor L-NMMA (1 mM) that also inhibited nitrite
accumulation, and by the sGC speci¢c inhibitor ODQ (1 mM)
(Table 1). Furthermore, both e¡ects were blocked by the IL-
1Ra (2 Wg/ml) indicating that they are mediated by IL-1 re-
ceptor-I (Table 1). Release of cGMP is not a result of cell
death or membrane leakage since LDH released to the me-
dium in cells treated with 10 ng/ml IL-1L for 20 h was no
di¡erent than in untreated cells (5.7 þ 2.7 and 7.1 þ 1.8% of
total, respectively). Accumulation of cGMP in the medium
but not in the cells was also observed in cortical and hippo-
campal astrocyte-enriched cultures treated with 10 ng/ml IL-
1L for 20 h (not shown), indicating that the IL-1L e¡ect is not
region speci¢c.
As previously shown by other authors in murine astroglial
cultures [16,17], nitrite accumulation induced by IL-1L was
potentiated 2^3-fold when cells were co-treated with INF-Q
(10 ng/ml) but not with TNF-K (10 ng/ml) (Fig. 2A,B). These
cytokines alone have little or no e¡ect on NO formation and
accordingly produce non-signi¢cant extra- and intracellular
cGMP accumulations. However, the combination of IL-1L
with INF-Q produced a larger accumulation of extracellular
cGMP than IL-1L alone in agreement with the higher NO
formation (Fig. 2A,B) but again intracellular cGMP was neg-
ligible (not shown). Thus stimulation of cGMP e¥ux appears
to be an IL-1L speci¢c e¡ect. This is further supported in
studies with LPS. Treatment of the cerebellar cultures with
10 ng/ml LPS for 20 h, that results in a much larger accumu-
lation of nitrites (IL-1L : 3.0 þ 0.6 WM; LPS: 17.5 þ 2.4 WM,
n = 6), induced accumulation of cGMP inside the cells with no
signi¢cant levels detected in the extracellular medium (Fig. 3).
However, when cells were treated with LPS together with IL-
1L there was no potentiation of nitrite formation (17.3 þ 2.9
WM, n = 6) but extracellular cGMP was 5-fold higher than
with IL-1L alone (Fig. 3), and intracellular cGMP tended to
decrease. These results indicate that IL-1L stimulates e¥ux of
cGMP generated in response to LPS. Probenecid (1 mM), a
non-selective inhibitor of organic anion transporters dimin-
ished the intracellular response to LPS by 54.2 þ 15.9%
(n = 3), probably by inhibiting sGC activity as reported to
occur in other cell types [16], but completely blocked the
IL-1L-induced extrusion of cGMP (Fig. 3). Another inhibitor
of anion transport, verapamil (10 WM), produced the same
e¡ect (Fig. 3). A probenecid-sensitive transporter for cGMP
has been reported to mediate extrusion of cGMP formed in
response to C-type natriuretic peptide in cortical astrocytes
[10], and in other cell types [5,7,18,19]. Results shown here
agree with the presence of such a transporter in astrocytes and
indicate that its capacity is increased by IL-1L. This is to our
knowledge the ¢rst report on the stimulation of cGMP extru-
sion from cells by an in£ammatory agent. In the CNS, IL-1L
Fig. 1. E¡ects of IL-1L on NO and cGMP formation in cerebellar
astroglia-enriched cultures. Cells were treated with 10 ng/ml IL-1L
for the indicated times (A, B) or with increasing IL-1L concentra-
tions for 20 h (C, D). Extracellular cGMP (a) and nitrites were de-
termined in the incubation media. Intracellular cGMP (b) was
determined in cells after washing the monolayers. Data are
means þ S.E.M. of three (A, B) and two (C, D) experiments per-
formed in di¡erent culture preparations.
Table 1
E¡ect of di¡erent agents on IL-1L-stimulated cGMP e¥ux and nitrite formation in cerebellar astroglia-enriched cultures
IL-1L e¡ect (%)
Extracellular cGMP Nitrites
Untreated IL-1L Untreated IL-1L
Control 1.1 þ 0.3 100 43 þ 6 100
L-NMMA, 1 mM 0.3 þ 0.1 2 þ 1.2 36 þ 13 40 þ 13
ODQ, 1 mM 0.4 þ 0.1 0.2 þ 0.1 ND ND
IL-1Ra, 2 Wg/ml 1.0 þ 0.3 16 þ 10 39 þ 6 43 þ 8
Cells were treated with IL-1L (10 ng/ml) for 20 h in the absence (untreated) or presence of the indicated compounds added 1 h before. Results,
expressed as percent of the e¡ect of IL-1L, are means þ S.E.M. of three to ¢ve experiments performed in triplicate in di¡erent culture prepara-
tions; ND, non-determined.
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is elevated during infection, trauma and neurodegenerative
diseases such as multiple sclerosis or Alzheimer’s disease, by
increased release from invading in£ammatory cells or from
reactive glial cells [20]. In these same cells and also in some
neuronal populations in£ammatory agents induce expression
of NOS and relatively high levels of NO can be generated for
prolonged periods of time [21,22]. NO and more reactive NO
derivatives have been repeatedly implicated in neurodegenera-
tion [23] although recent reports suggest a neuroprotective
role of NO acting as an antioxidant [24]. cGMP, the well
recognized physiological second messenger of NO can be
formed in neurons and in astrocytes [25,26] and has also
been implicated in neuroprotective e¡ects [9]. However, there
is very little known about the regulation of cGMP formation
under in£ammatory conditions. We have recently shown that
sGC is down-regulated in astroglial cells by LPS treatment
[15]. This could be a mechanism to control cGMP formation
under conditions of high NO output. The stimulation by IL-
1L of cGMP e¥ux reported here may be an additional mech-
anism to keep intracellular cGMP levels low. Alternatively,
egressed cGMP may play a role during neuroin£ammation
by regulating the function of membrane proteins as shown
for the Na/H exchanger in astrocytes [10] and for kainate
receptors in neurons [8]. Whether these extracellular actions of
cGMP contribute to neurodegeneration or otherwise prevent
it, as suggested by the demonstration that extracellular cGMP
protects neurons against glutamate-induced toxicity [9], de-
serves investigation.
Acknowledgements: We thank Francisca Garc|¤a for assistance in
preparation of cultures. This work was supported by DGICYT
(PB97-0728), Fundacio¤ La Marato¤ TV3 (1008/97) and DGR
(SGR99-00123) Grants. C.E. Pedraza is the recipient of a predoctoral
fellowship from Ministerio de Educacio¤n y Cultura (Spain).
References
[1] Ashman, D.F., Lipton, R., Melicow, M.M. and Price, T.D.
(1963) Biochem. Biophys. Res. Commun. 11, 330^334.
[2] Tjo«rnhammar, M.L., Lazaridis, G. and Bartfay, T. (1983) J. Biol.
Chem. 258, 6882^6886.
[3] Tjo«rnhammar, M.L., Lazaridis, G. and Bartfay, T. (1986) Neuro-
sci. Lett. 68, 95^99.
[4] Kapoor, C.L. and Krishna, G. (1977) Science 196, 1003^1005.
[5] Hamet, P., Pang, S.C. and Tremblay, J. (1989) J. Biol. Chem.
264, 12363^12369.
[6] Wu, X.B., Brune, B., Von Appen, F. and Ullrich, V. (1993) Mol.
Pharmacol. 43, 564^568.
Fig. 2. Extracellular cGMP (A) and nitrites (B) accumulation in cer-
ebellar astroglia-enriched cultures treated with pro-in£ammatory cy-
tokines. Cultures were treated with 10 ng/ml IL-1L, INF-Q or TNF-
K alone or in combination, for 20 h and cGMP and nitrites deter-
mined in the incubation media. Intracellular cGMP was negligible
in all cases. Data are means þ S.E.M. of three independent experi-
ments.
Fig. 3. E¡ect of probenecid and verapamil on intracellular and
extracellular cGMP accumulation in astrocyte-enriched cultures
treated with IL-1L and LPS. Cells were incubated with 10 ng/ml
LPS, IL-1L or both for 20 h, in the absence or presence of probene-
cid (1 mM) or verapamil (10 WM) that were added 1 h before.
Extracellular cGMP and nitrites were measured in the extracellular
media. Monolayers were washed and collected for intracellular
cGMP determination. Data are means þ S.D. of triplicate determina-
tions in a representative experiment that was repeated six times
without inhibitors, three with probenecid and two with verapamil in
di¡erent culture preparations.
FEBS 25396 26-10-01
C.E. Pedraza et al./FEBS Letters 507 (2001) 303^306 305
[7] Schultz, C., Vaskinn, S., Kildalsen, H. and Sager, G. (1998) Bio-
chemistry 37, 1161^1166.
[8] Pouloupoulou, C. and Nowak, L. (1998) J. Pharmacol. Exp.
Ther. 286, 99^109.
[9] Montoliu, C., Llansola, M., Kosenko, E., Corbalan, R. and Fe-
lipo, V. (1999) Neuropharmacolgy 38, 1883^1891.
[10] Touyz, R.M., Picard, S., Sch¡rin, E.L. and Deschepper, C.F.
(1997) J. Neurochem. 68, 1451^1461.
[11] Brooker, G., Harper, J.F., Terasaki, W.L. and Moylan, R.D.
(1979) Adv. Cyclic Nucleotide Res. 10, 1^33.
[12] Agullo¤ , L., Baltrons, M.A. and Garc|¤a, A. (1995) Brain Res. 686,
160^168.
[13] Klegeris, A. and McGeer, P.L. (1997) J. Neurosci. Res. 49, 229^
235.
[14] Agullo¤ , L. and Garc|¤a, A. (1992) Biochem. J. 288, 619^624.
[15] Baltrons, M.A. and Garc|¤a, A. (1999) J. Neurochem. 72, 2149^
2157.
[16] Hewett, S.J., Corbett, J.A., McDaniel, M.L. and Choi, D.W.
(1993) Neurosci. Lett. 164, 229^232.
[17] Simmons, M.L. and Murphy, S. (1993) Eur. J. Neurosci. 5, 825^
831.
[18] Patel, M.J., Wypij, D.M., Rose, D.A., Thomas, J.R. and Wise-
man, J.S. (1995) J. Pharmacol. Exp. Ther. 273, 16^25.
[19] Billiar, T.R., Curran, R.D., Harbrecht, B.G., Stadler, J., Wil-
liams, D.L., Ochoa, J.B., Di Silvio, M., Simmons, R.L. and
Murray, S.A. (1992) Am. J. Physiol. 262, 1077^1082.
[20] Rothwell, N.J. and Luheshi, G.N. (2000) Trends Neurosci. 23,
618^625.
[21] Murphy, S. (2000) Glia 29, 1^13.
[22] Heneka, M.T. and Feinstein, D.L. (2001) J. Neuroimmunol. 114,
8^18.
[23] Dawson, V.L. and Dawson, T.M. (1998) Prog. Brain Res. 118,
215^229.
[24] Sinz, E.H., Kochanek, P.M, Dixon, C.E., Clark, R.S.B., Carcillo,
J.A., Schiding, J.K., Chen, M., Wisniewski, St.R., Carlos, T.M.,
Williams, D., Dekosky, St.T., Watkins, S.C., Marion, D.W. and
Billiar, T.M. (1999) J. Clin. Invest. 104, 647^656.
[25] Garthwaite, J. and Boulton, C.L. (1995) Annu. Rev. Physiol. 57,
683^706.
[26] Baltrons, M.A. and Garc|¤a, A. (2001) Prog. Brain Res. 132, 335^
347.
FEBS 25396 26-10-01
C.E. Pedraza et al./FEBS Letters 507 (2001) 303^306306
